Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate‐specific antigen complexed to α1‐antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.

[1]  Walter J Koroshetz,et al.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.

[2]  J. D. Adams.  Alzheimer's disease, ceramide, visfatin and NAD. , 2008, CNS & neurological disorders drug targets.

[3]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[4]  R. W. Gracy,et al.  Identification of oxidized plasma proteins in Alzheimer's disease. , 2002, Biochemical and biophysical research communications.

[5]  E. Diamandis,et al.  Prostate-specific antigen in cerebrospinal fluid. , 1997, Clinical chemistry.

[6]  K. Blennow,et al.  Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. , 2010, Journal of Alzheimer's disease : JAD.

[7]  Albert Hofman,et al.  Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.

[8]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[9]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[10]  F Kruggel,et al.  Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly , 2001, Neurobiology of Aging.

[11]  Mattias Ohlsson,et al.  Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease , 2012, PloS one.

[12]  N. Tabet,et al.  Plasma fetuin-A is associated with the severity of cognitive impairment in mild-to-moderate Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[13]  Guanghua Xiao,et al.  A serum protein-based algorithm for the detection of Alzheimer disease. , 2010, Archives of neurology.

[14]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[15]  Chris Frost,et al.  Does Alzheimer’s Disease Affect Hippocampal Asymmetry? Evidence from a Cross-Sectional and Longitudinal Volumetric MRI Study , 2005, Dementia and Geriatric Cognitive Disorders.

[16]  Eileen Daly,et al.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.

[17]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[18]  Frederik Barkhof,et al.  CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease , 2008, Neurobiology of Aging.

[19]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[20]  H. Potter,et al.  α 1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α 1-antichymotrypsin , 1990, Neurobiology of Aging.

[21]  H. Hampel,et al.  Blood-Based Microcirculation Markers in Alzheimer's Disease–Diagnostic Value of Midregional Pro-atrial Natriuretic Peptide/C-terminal Endothelin-1 Precursor Fragment Ratio , 2009, Biological Psychiatry.

[22]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[23]  Nelleke Tolboom,et al.  Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding , 2009, Journal of Nuclear Medicine.

[24]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[25]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[26]  Guanghua Xiao,et al.  A Blood-Based Algorithm for the Detection of Alzheimer’s Disease , 2011, Dementia and Geriatric Cognitive Disorders.

[27]  Timothy M. Klein,et al.  Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model , 2010, BMC Medical Informatics Decis. Mak..

[28]  D. Cucinotta,et al.  Acute Phase Reactant α1Antichymotrypsin Is Increased in Cerebrospinal Fluid and Serum of Patients with Probable Alzheimer Disease , 1995, Alzheimer disease and associated disorders.

[29]  Chunshui Yu,et al.  Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer's disease: Meta‐analyses of MRI studies , 2009, Hippocampus.

[30]  P. Lewczuk,et al.  Multidimensional plasma protein separation technique for identification of potential Alzheimer’s disease plasma biomarkers: a pilot study , 2012, Journal of Neural Transmission.

[31]  M. Cookson,et al.  The Metalloprotease Inhibitor TIMP-3 Regulates Amyloid Precursor Protein and Apolipoprotein E Receptor Proteolysis , 2007, The Journal of Neuroscience.

[32]  Magda Tsolaki,et al.  The AddNeuroMed framework for multi‐centre MRI assessment of Alzheimer's disease : experience from the first 24 months , 2011, International journal of geriatric psychiatry.

[33]  H. Potter,et al.  Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. , 1990, Neurobiology of aging.

[34]  W. Jahnen-Dechent,et al.  Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. , 2003, The Biochemical journal.

[35]  S. Hirai,et al.  Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.

[36]  D. Bennett,et al.  Chronic Psychological Distress and Risk of Alzheimer’s Disease in Old Age , 2006, Neuroepidemiology.

[37]  P. Scheltens,et al.  CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[38]  Katharina Buerger,et al.  Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum , 2009, CNS neuroscience & therapeutics.

[39]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[40]  A. Simmons,et al.  MRI Measures of Alzheimer's Disease and the AddNeuroMed Study , 2009, Annals of the New York Academy of Sciences.

[41]  H. Chertkow,et al.  Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma , 2003, Proteomics.

[42]  A. Simmons,et al.  Regional Magnetic Resonance Imaging Measures for Multivariate Analysis in Alzheimer’s Disease and Mild Cognitive Impairment , 2012, Brain Topography.

[43]  A. Hofman,et al.  Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease. , 2011, Journal of proteome research.

[44]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[45]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[46]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[47]  S. Lovestone,et al.  Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease , 2004, Neuroscience Letters.

[48]  S. Hirai,et al.  α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .

[49]  S. Lovestone,et al.  Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper , 2009, The journal of nutrition, health & aging.

[50]  P. Wesseling,et al.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. , 1999, The American journal of pathology.

[51]  A. Simmons,et al.  AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.

[52]  Pieter Visser,et al.  Faculty Opinions recommendation of Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. , 2006 .

[53]  Michael Weiner,et al.  Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.

[54]  P. Liao,et al.  Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[55]  Deborah Pinchev,et al.  Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.

[56]  S Lovestone,et al.  Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed. , 2007, The journal of nutrition, health & aging.

[57]  Magda Tsolaki,et al.  Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden , 2012, PloS one.